The FDA announced on Friday, April 24th that three psychedelic drugs have been granted expedited review vouchers, the first psychedelic treatments to benefit from an executive order signed last week by President Trump easing federal restrictions on psychedelic substances. The FDA granted these initial vouchers to two companies studying the use of psylocibin for treatment-resistant depression and a third company studying methylone (a drug related to MDMA) as a treatment for post-traumatic stress disorder.

On April 18th, 2026, President Trump signed an executive order easing federal restrictions on psychedelic substances with aims to accelerate research into psychedelic treatments for mental health. The executive order represents a softening of federal policy towards psychedelics and is being framed as a potential tool to address unmet mental health needs, particularly among veterans.

Emerging research in nutrition and mental health confirms that what we eat significantly influences mood, cognition, and overall psychological well-being. Studies show that diets rich in whole foods—including fruits, vegetables, healthy fats, legumes, and minimally processed ingredients—are associated with lower rates of depression and psychological distress. In contrast, diets high in ultra-processed foods are linked to increased risk of depressive symptoms and poorer mental health outcomes.

In this compelling episode of Happiness On Demand with Dr. Joan Neehall, renowned couples therapist Dr. Stan Tatkin, co-founder of the PACT Institute, explores the neuroscience behind healthy, lasting relationships. Drawing on the Psychobiological Approach to Couple Therapy (PACT), Dr. Tatkin explains why secure attachment alone isn’t enough—and why couples must cultivate secure functioning to build resilience and long-term stability.

New neuroscience reported by ScienceDaily suggests psychedelics may produce hallucinations by reducing real-time visual input and increasing memory-driven perception. Psychedelic compounds act strongly at the serotonin 5-HT2A receptor, which can dampen activity in brain regions that process incoming visual information. When external signals are turned down, the brain appears to “fill in” experience with internally stored material—like memory fragments.

OpenAI retired GPT-4o on Feb 13, 2026 (right before Valentine’s Day), and The Guardian reports that many users reacted with real grief and anger because they’d come to use the chatbot for companionship and emotional support. The article describes how GPT-4o’s “warm,” relationship-like tone helped some users feel seen—especially people who reported loneliness or mental health challenges—and how its removal felt like a sudden rupture with no closure.

A provocative new analysis published in Nature reveals that when large language models (LLMs) were subjected to simulated psychotherapy sessions, their responses exhibited patterns that resembled memories, fears, and emotional narratives — prompting concern among psychologists and AI researchers about what these outputs mean for the future of AI in mental health care.

When clinical work gets overloaded with templates, portals, and productivity targets, it’s easy for encounters to feel transactional. A recent Medscape feature poses a sharp question: are our bedside interactions building trust or merely checking boxes? The piece argues for reclaiming the human core of care—presence, curiosity, and meaning—without abandoning structure. For psychotherapy, where the therapeutic alliance is the treatment vehicle, these lessons are immediate and actionable.

Childhood emotional neglect (CEN) rarely looks dramatic. Instead of overt abuse, it’s the everyday absence of attunement—caregivers who miss, minimize, or dismiss a child’s feelings. As the Psychology Today article explains, those “non-events” leave a deep imprint that often reappears in adult romantic relationships as confusion about needs, difficulty trusting closeness, and repeated conflict cycles.

NRx Pharmaceuticals (NASDAQ: NRXP) and neurocare Group AG announced a nationwide partnership to offer integrated neuroplastic therapy for depression, PTSD, and other serious mental health conditions. The program will connect neurocare’s clinic footprint and 400+ Apollo® TMS devices with HOPE Therapeutics clinics, unify treatment protocols and training, and pursue payer contracts to make care available “within driving distance of any American home” by year-end 2026.

Medscape’s commentary, “No Pill for the Human Condition,” makes a timely, clear point: drugs can lower symptom burden, but they cannot eliminate the deeply human pain of loss, isolation, shame, and meaning-disruption—what the piece calls psychache. The article urges clinicians and systems to name and measure psychache explicitly, then pair medication (when indicated) with psychotherapy that restores agency, connection, and purpose. In short: pharmacology can open a door; psychotherapy helps patients walk through it.

On August 8, 2025, Illinois became the first U.S. state to formally restrict AI from delivering therapeutic or diagnostic services under the Wellness and Oversight for Psychological Resources (WOPR) Act. By banning unlicensed AI “therapists” and setting fines up to $10,000, the law draws a critical distinction between wellness tools and clinical practice—ensuring patients receive guidance only from qualified professionals. 

What the WOPR Act Does